Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer.
Bioniz leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bioniz-llc” connections=”true” suffix=””]
Bioniz Therapeutics leverages its proprietary platform technology to develop novel peptides that target functionally redundant cytokines with targeted specificity.
In Aug 2016, Bioniz raised $13 Mn in its Series A funding co-led by Takeda Ventures Inc., and Dr. David Pyott, and also includes investments from Mr. Joe Kiani, and Cota Capital.
Recover your password.
A password will be e-mailed to you.